Characteristics | Adalimumab, n = 204 | Etanercept, n = 290 | Infliximab, n = 69 |
---|---|---|---|
Age, mean yrs (95% CI) | 60.3 (58.8, 61.8) | 59.8 (58.6, 61.1) | 64.8 (62.5, 67.1) |
Sex, men | 185 (91) [87, 95] | 261 (90) [87, 93] | 62 (90) [83, 97] |
Race | |||
White | 146 (72) [65, 78] | 227 (78) [74, 83] | 51 (74) [64, 84] |
African American | 43 (21) [15, 27] | 41 (14) [10, 18] | 16 (23) [13, 33] |
Hispanic | 7 (3) [1, 6] | 13 (4) [2, 7] | 2 (3) [0, 7] |
American Indian/Pacific Islander | 4 (2) [0, 0.4] | 4 (1) [0, 3] | 0 (0) [0, 0] |
Asian | 0 (0) [0, 0] | 1 (< 1) [0, 1] | 0 (0) [0, 0] |
Other/unknown | 4 (2) [0, 4] | 4 (1) [0, 3] | 0 (0) [0, 0] |
Tobacco use | |||
Current | 63 (31) [25, 37] | 102 (35) [3, 41] | 16 (23) [13, 33] |
Former | 104 (51) [44, 58] | 126 (43) [38, 49] | 39 (57) [45, 68] |
Never | 37 (18) [13, 23] | 62 (21) [17, 26] | 14 (20) [11, 30] |
RF-positive | 160 (78) [73, 83] | 231 (80) [75, 84] | 57 (83) [72, 90] |
RA disease duration, mean yrs (95% CI) | 9.7 (8.4, 11.1) | 10.5 (9.3, 11.7) | 12.4 (9.9, 14.8) |
DMARD use during TNFi therapy | |||
None | 28 (14) [9, 18] | 50 (17) [13, 22] | 2 (3) [0, 7] |
Any | 176 (86) [82, 91] | 240 (83) [78, 87] | 67 (97) [93, 100] |
Methotrexate | 118 (58) [51, 65] | 181 (62) [57, 68] | 47 (68) [57, 79] |
Hydroxychloroquine | 81 (40) [33, 46] | 92 (32) [26, 37] | 29 (42) [30, 54] |
Sulfasalazine | 37 (18) [13, 23] | 53 (18) [14, 23] | 13 (19) [10, 28] |
Leflunomide | 35 (17) [12, 22] | 42 (14) [10, 19] | 16 (23) [13, 33] |
Azathioprine | 11 (5) [2, 8] | 6 (2) [0, 4] | 4 (6) [0, 11] |
Minocycline | 2 (1) [0, 2] | 8 (3) [1, 5] | 1 (< 1) [0, 4] |
Auranofin | 1 (< 1) [0, 1] | 1 (< 1) [0, 1] | 0 (0) [0, 0] |
Prednisone use | 117 (57) [51, 64] | 168 (58) [52, 64] | 48 (70) [59, 80] |
RA: rheumatoid arthritis; TNFi: tumor necrosis factor inhibitor; RF: rheumatoid factor; DMARD: disease-modifying antirheumatic drug.